ESR1 and breast carcinoma: In breast cancers, estrogen receptor (ER) status seems to profoundly influence the rate of relapse: ER− patients tend to recur within the first 5 years following primary tumor diagnosis, while ER+ patients have increased risk between 5 and 20 years (Pan et al., 2017; Pantel and Hayes, 2018).